Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a conference call and live webcast on Thursday, May 3, 2018 at 8:00 A.M. ET to report its first quarter 2018 financial results and to discuss recent business updates.
Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. Sage's lead program, a proprietary IV formulation of brexanolone (SAGE-547), has completed Phase 3 clinical development for postpartum depression. Sage is developing its next generation modulators, including SAGE-217 and SAGE-718, in various CNS disorders. For more information, please visit www.sagerx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180424005270/en/
Contacts
Sage Therapeutics
Investor Contact:
Paul Cox, 617-299-8377
paul.cox@sagerx.com
or
Media Contact:
Maureen L. Suda, 585-355-1134
maureen.suda@sagerx.com
Source: Sage Therapeutics
View this news release online at:
http://www.businesswire.com/news/home/20180424005270/en
